stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Revenue growth
Kymera Therapeutics, Inc.'s revenue growth over the twelve months to 30 June 2026 was 134.8%, up 151.5 percentage points from fiscal 2025 (−16.7%). Over the past ten years it has ranged from −91.4% (fiscal 2019) to 1,060.0% (fiscal 2020); the current reading is higher than 57% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −16.7% | 23.41 |
| FY2024 | −40.1% | (107.95) |
| FY2023 | 67.8% | 103.55 |
| FY2022 | −35.7% | (149.71) |
| FY2021 | 114.0% | (945.99) |
| FY2020 | 1,060.0% | 1,151.37 |
| FY2019 | −91.4% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 466.4% | 410.90 |
| Mar 2026 | 55.5% | 116.67 |
| Dec 2025 | −61.2% | (35.05) |
| Sep 2025 | −26.1% | 29.14 |
| 23 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| IBRX ImmunityBio, Inc. compare | 192.9% |
| KYMR Kymera Therapeutics, Inc. | 134.8% |
| TGTX TG Therapeutics, Inc. compare | 76.1% |
| CAI Caris Life Sciences,�Inc. compare | 68.8% |
| TWST Twist Bioscience Corporation compare | 19.2% |
| BMRN BioMarin Pharmaceutical Inc. compare | 18.1% |
| TECH Bio-Techne Corp compare | −0.38% |
| SMMT Summit Therapeutics PLC compare | −61.0% |
| PCVX Vaxcyte, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement